PSNL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Personalis Inc (PSNL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has some positive developments in its product offerings and improving financial metrics, the technical indicators and trading trends do not suggest a strong upward momentum. Additionally, there are no significant proprietary trading signals or influential trading activity to support an immediate buy decision.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral at 57.235, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels are at 6.788 and 7.045, while support levels are at 5.955 and 5.698. Overall, the technical indicators suggest a mixed trend with no clear buy signal.
Personalis is presenting new findings and product advancements at the 2026 AACR Annual Meeting, which could enhance its reputation in colorectal cancer management. The company's Real-Time Variant Tracker and ctDNA monitoring innovations are promising for long-term growth.
The stock has a high probability of short-term price declines (-0.94% in the next day, -3.67% in the next week, -7.25% in the next month). Analysts have also lowered price targets recently, reflecting concerns about higher operating expenses and net loss guidance.
In Q4 2025, revenue increased by 3.24% YoY, and net income improved by 44.97% YoY, showing some progress. However, the gross margin dropped significantly by -59.56% YoY, which raises concerns about profitability.
Morgan Stanley recently lowered its price target to $10 from $11, maintaining an Equal Weight rating. Guggenheim raised its price target to $13 from $12 with a Buy rating. Analyst sentiment is mixed, with concerns about higher expenses but optimism about the company's product pipeline.
